Intensive Chemotherapy (LNHIV-91 Regimen) and G-CSF for HIV Associated Non-Hodgkin's Lymphoma

Abstract

The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL). Fifty two consecutive patients with HIV infection, agressive NHL and CD4+ cells ≥ 100 × 106/1 were included. The median CD4 cell count was 276 × 106/1. Nineteen tumors were of the Burkitt's type, 23 were large cells, 7 immunoblastic, and 3 anaplastic. Twenty-five patients had stage IV disease (bone marrow involvement in 7, and central nervous system in 9). Three cycles of ACVBP (doxorubicine, cyclophosphamide, vindesine, bleomycin, prednisolone) were given. A fourth cycle was delivered to patients in partial remission or with initial bulky disease. The induction was followed by three cycles of CVM (cyclophosphamide, etoposide, methotrexate). G-CSF 5 μ/kg was used at each cycle. Results showed that 37 patients (71%) achieved a complete remission. With a median follow-up of 74 months, 8 of them have relapsed. The median survival was 15 months and 34 patients have died (21 with NHL). The 4-year estimate survival was 33,9% (95% CI, 19,8%–47,4%). The Relative Dose-Intensity of the chemotherapy was 85% for doxorubicine and 87% for cyclophosphamide. In a multivariate analysis, homosexual men and patients with ECOG < 2 had a lower risk for death: RR = 0,32 (95% CI, 0,15–0,65) and RR = 0,36 (95% CI, 0,18–0,74), respectively. Achievement of complete remission was strongly associated with survival. In conclusion, it seems that in HIV-infected patients with NHL and a CD4 cell count above 100 × 10⁶/1, high complete remission rate and prolonged survival can be achieved with the intensive LNHIV-91 regimen.

Key Words:

• Non-Hodgkin's lymphoma
• HIV
• chemotherapy
• G-CSF